Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Linagliptin

FDA-approved product (tablet, oral), marketed as Linagliptin, Tradjenta.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Linagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Linagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Linagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Linagliptin Inpatient Trial

    NCT02004366 · start 2014-01

    Registered record
    Registry ID
    NCT02004366
    Conditions
    Type 2 Diabetes
    Interventions
    Linagliptin; Basal Bolus; Linagliptin; Linagliptin + 50% Glargine dose on discharge; Linagliptin + 80% Glargine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01
    Completion
    2017-03
    Enrolment
    295

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionLinagliptin; Basal Bolus; Linagliptin; Linagliptin + 50% Glargine dose on discharge +1 more
    PhasePhase 4
    Registry statusCompleted

  • Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment

    NCT01903070 · start 2013-07-11

    Registered record
    Registry ID
    NCT01903070
    Conditions
    Diabetes Mellitus
    Interventions
    Linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-07-11
    Completion
    2016-04
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus
    InterventionLinagliptin
    PhasePhase 4
    Registry statusCompleted

  • Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria

    NCT02376075 · start 2013-01

    Registered record
    Registry ID
    NCT02376075
    Conditions
    Arterial Hypertension; Albuminuria
    Interventions
    Linagliptin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-09
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension; Albuminuria
    InterventionLinagliptin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus

    NCT01547104 · start 2012-04

    Registered record
    Registry ID
    NCT01547104
    Conditions
    Diabetes Mellitus Type 2
    Interventions
    Linagliptin; Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-04
    Completion
    2012-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus Type 2
    InterventionLinagliptin; Glimepiride
    PhasePhase 4
    Registry statusUnknown

  • Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

    NCT01581931 · start 2012-04

    Registered record
    Registry ID
    NCT01581931
    Conditions
    Healthy
    Interventions
    Linagliptin/metformin; Metformin; Linagliptin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLinagliptin/metformin; Metformin; Linagliptin
    PhasePhase 1
    Registry statusCompleted

  • 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

    NCT01183013 · start 2010-08

    Registered record
    Registry ID
    NCT01183013
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Pioglitazone 15 mg; Pioglitazone 45 mg; Pioglitazone 30 mg; Linagliptin 5mg / Pioglitazone 45 mg FDC; Linagliptin 5mg / Pioglitazone 30 mg FDC; Linagliptin 5mg; Linagliptin 5mg / Pioglitazone 15 mg FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2013-02
    Enrolment
    936

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionPioglitazone 15 mg; Pioglitazone 45 mg; Pioglitazone 30 mg; Linagliptin 5mg / Pioglitazone 45 mg FDC +3 more
    PhasePhase 3
    Registry statusCompleted

  • Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

    NCT01189201 · start 2010-08

    Registered record
    Registry ID
    NCT01189201
    Conditions
    Healthy
    Interventions
    BI 10773/linagliptin; BI 10773/linagliptin; BI 10773/linagliptin SID; BI 10773/linagliptin FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    Not recorded
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 10773/linagliptin; BI 10773/linagliptin; BI 10773/linagliptin SID; BI 10773/linagliptin FDC
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

    NCT02221414 · start 2010-01

    Registered record
    Registry ID
    NCT02221414
    Conditions
    Healthy
    Interventions
    Linagliptin/Metformin FDC; Linagliptin; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    Not recorded
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLinagliptin/Metformin FDC; Linagliptin; Metformin
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

    NCT02183636 · start 2009-08

    Registered record
    Registry ID
    NCT02183636
    Conditions
    Healthy
    Interventions
    Linagliptin/pioglitazone, FDC formulation C5; Linagliptin/pioglitazone, FDC formulation C8; Linagliptin tablet; pioglitazone tablet (Actos®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    Not recorded
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLinagliptin/pioglitazone, FDC formulation C5; Linagliptin/pioglitazone, FDC formulation C8; Linagliptin tablet; pioglitazone tablet (Actos®)
    PhasePhase 1
    Registry statusCompleted

  • Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

    NCT02173639 · start 2009-04

    Registered record
    Registry ID
    NCT02173639
    Conditions
    Healthy
    Interventions
    BI 1356/metformin; BI 1356; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 1356/metformin; BI 1356; Metformin
    PhasePhase 1
    Registry statusCompleted

  • Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

    NCT00819091 · start 2008-12

    Registered record
    Registry ID
    NCT00819091
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    BI 1356; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12
    Completion
    Not recorded
    Enrolment
    245

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionBI 1356; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

    NCT02183376 · start 2008-07

    Registered record
    Registry ID
    NCT02183376
    Conditions
    Hepatic Insufficiency
    Interventions
    BI 1356
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-07
    Completion
    Not recorded
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Insufficiency
    InterventionBI 1356
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers

    NCT02183402 · start 2008-06

    Registered record
    Registry ID
    NCT02183402
    Conditions
    Healthy
    Interventions
    Digoxin; BI 1356
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDigoxin; BI 1356
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

    NCT00621140 · start 2008-02

    Registered record
    Registry ID
    NCT00621140
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    linagliptin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    503

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    Interventionlinagliptin; placebo
    PhasePhase 3
    Registry statusCompleted

  • BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

    NCT02183324 · start 2007-02

    Registered record
    Registry ID
    NCT02183324
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Low dose of BI 1356 BS; Medium dose of BI 1356 BS; High dose of BI 1356 BS; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    Not recorded
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionLow dose of BI 1356 BS; Medium dose of BI 1356 BS; High dose of BI 1356 BS; Placebo
    PhasePhase 2
    Registry statusCompleted